688073 毕得医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.6935.7055.26110.79319.650
总资产报酬率 ROA (%)2.9674.8594.5908.94113.803
投入资产回报率 ROIC (%)3.3405.4105.06210.38018.355

边际利润分析
销售毛利率 (%)44.25141.33340.00044.37849.459
营业利润率 (%)16.03713.46011.59820.59618.912
息税前利润/营业总收入 (%)16.73611.4508.83318.45719.725
净利润/营业总收入 (%)11.69810.6569.93217.50616.095

收益指标分析
经营活动净收益/利润总额(%)104.220114.935120.092100.850100.307
价值变动净收益/利润总额(%)7.3873.221-7.042-0.2350.356
营业外收支净额/利润总额(%)0.203-0.214-0.5020.022-0.075

偿债能力分析
流动比率 (X)4.3056.3888.2239.0123.277
速动比率 (X)2.7374.1895.6806.9171.367
资产负债率 (%)22.98116.16713.47811.99830.599
带息债务/全部投入资本 (%)11.3413.7692.1771.4472.198
股东权益/带息债务 (%)766.4722,497.9354,387.9926,700.5924,261.866
股东权益/负债合计 (%)335.141518.561641.976733.488226.804
利息保障倍数 (X)25.136-5.778-3.263-8.61023.836

营运能力分析
应收账款周转天数 (天)68.47574.80367.92765.12962.240
存货周转天数 (天)414.429406.386335.560387.482408.530